

________________________________________________________________
Riga 6 supera TOK_MAX (2592 > 1700) – saltata.

outcome_measurement_title:
Multiple Mood States: Profile of Mood States (POMS)-Fatigue Scale;
Multiple Mood States: Profile of Mood States (POMS)-Anger Scale;
Plasma Concentrations of Isoflavones at Month 6;
Measure of Selective Attention: Time to Complete Stroop Color Word Test;
Cognitive Outcomes - Language Executive Function : Category Fluency Assessed as Number of Words Generated/Min;
Cognitive Outcomes-Global Cognition : Mini-Mental State Examination (MMSE) Score;
Plasma Concentrations of Isoflavones at Baseline;
Visual Memory : Benton Visual Retention Test: Number of Correct Figures;
A Test of Planning: Time to Complete Mazes;
Multiple Mood States: Profile of Mood States (POMS)-Depression Scale;
Cognitive Outcomes - Visual Motor : Time to Complete Grooved Pegboard Test Using the Dominant Hand;
Number of Participants With ApoE4 Allele;
Immediate and Delayed Recall on Verbal Memory/ Logical Memory Immediate and Delayed Recall: Number of Story Elements Recalled;
Geriatric Depression Scale-Subject Report;
Immediate and Delayed Recall on Verbal Memory/ List Learning Immediate and Delayed Free Recall: Number of Words Recalled;
Visual Memory Test: Complex Figure Delayed Recall; Number of Points;
Cognitive Outcomes - Visual Memory : Benton Visual Retention; Number of Errors;
Geriatric Depression Scale-Study Partner Report;
Cognitive Outcomes - Visual Motor : Time to Complete Grooved Pegboard Test Using the Non-Dominant Hand;
Measure of Divided Attention: Time to Complete Trail Making Test B;
Cognitive Outcomes - Visual Motor : Complex Figure Copy; Number of Points;
Plasma Concentrations of Isoflavones at Month 3;
Cognitive Outcomes - Language Executive Function : Phonemic Fluency/Verbal Fluency Assessed as Number of Words Generated Per Minute;
Multiple Mood States: Profile of Mood States (POMS)-Vigor Scale;
Multiple Mood States: Profile of Mood States (POMS)-Tension Scale;
Multiple Mood States: Profile of Mood States (POMS)-Confusion Scale;


________________________________________________________________
Riga 9 supera TOK_MAX (3538 > 1700) – saltata.

outcome_measurement_title:
Number of Participants With Clinical Chemistry Data of PCC at End of the Treatment (Month 12);
Number of Participants With Heart Rate/ Pulse Rate Outside the Concern Range at Month 12;
Number of Participants With Hematological Data of Potential Clinical Concern (PCC) at End of Treatment (Month 12);
Change From Baseline in Neuropsychiatric Inventory Score Over Period;
Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Parameters at Screening and Follow-up;
Change From Baseline (Day 1) in Delayed Free Recall Items Over Period by Stroop Colour Word Interference (SCWI) at Months 1, 6 and 12;
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Scale (ADAS-COG) Total Score Over Period;
Change From Baseline in Cognitive Test by Simple Reaction Time (SRT) Method Over Period;
Change From Baseline in Lipid (Cholesterol) and Apo-lipoprotein Levels at Month 12;
Change From Baseline (Day 1) in Delayed Free Recall Words at Months 1, 6, and 12 by Buschke Selective Reminding (BSR) Test;
Percent Change From Baseline in Brain Volume Over Period;
Number of Participants With Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Outside the Concern Range at Month 12;
Change From Baseline in Normalized Brain Volume Over Period;
Change From Baseline in Insulin Sensitivity Measured by Homeostasis Model Assessment of Insulin Resistance (HOMA IR);
Change From Baseline (Day 1) in CMRGlu Indices at Months 1 and 6;
Change From Baseline in Mini-mental State Examination (MMSE) Score Over Period;
Global and Regional CMRglu Index by APOE Epsilon-4 Allele Subtype at 12 Month;
Change From Baseline (Day 1) in Simplified Spatial Paired Associate Learning (SSPAL) Response Over Period;
Change From Baseline in Fasting Plasma Glucose at Month 12;
Change From Baseline in Inflammatory Biomarkers (CD40, C-reactive Protein [CRP] , Interleukin [ IL ]-6, and Tumor Necrosing Factor [TNF]-Alpha);
Change From Baseline (Day 1) in Accuracy by Choice Reaction Time (CRT) Test Over Period;
Change From Baseline in Clinician Based Impression of Change-plus (CBIC +) Score Over Period;
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);
Change From Baseline in Glycosylated Hemoglobin [HbA1C] at Month 12;
Number of Participants With Body Weight and Height Outside the Clinical Concern at Month 12;
Change From Baseline (Day 1) in Global and Regional Indices of Cerebral Metabolic Rate of Glucose (CMRglu) at Month 12;
Number of Participants by Apo-lipoprotein -e (APOE Epsilon)-4 Allele Subtype;


________________________________________________________________
Riga 13 supera TOK_MAX (4923 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline in European Quality of Life -5 Dimensions (EQ-5D) Scale Total Score- Thermometer Score;
Change From Baseline in CDR-SB Score at Week 48, as a Function of APOE ε4 Status in Full Population Cohort;
Any Time on Treatment Differences in Frequencies of Clinical Chemistry Data Outside the Reference Range;
Change From Baseline in HbA1c up to Week 54;
Change From Baseline in Hemoglobin;
Change From Baseline in ADAS-Cog Total Score at Week 48, as a Function of APOE ε4 Status in Full Population Cohort;
Change From Baseline in CDR-SB Score at Week 48, as a Function of APOE ε4 Status in All Except E4/E4s Cohort;
Change From Baseline in ADAS-Cog Total Score at Weeks 8, 16, 24 and 36;
Number of Participants With On-treatment Adverse Events (AEs), Serious Adverse Events (SAEs) and Severity of AEs;
Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP);
Change From Baseline in ADAS-Cog Total Score at Week 48, as a Function of APOE ε4 Status in All Except E4/E4s Cohort;
Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives Cohort;
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score;
Change From Baseline in Short Term Memory Assessment;
Change From Baseline in Weight;
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48, as a Function of APOE ε4 Status in APOE4 Negatives Cohort;
Change From Screening in Mini Mental State Examination (MMSE) Total Score;
Changes From Baseline in Electrocardiogram (ECG) Parameters- HR;
Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48;
Change From Baseline in Hematocrit;
Changes From Baseline in ECG Parameters- RR Interval, QT Interval, QTcB, QTcF, PR Interval and QRS Duration;
Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Heart Rate (HR);
Change From Baseline in Alzheimer's Carer's Quality of Life Instrument (ACQLI) Score;
Change From Baseline in Domains of the Resource Utilization in Dementia Scale (RUD)- Q1 and Q2 Caregiver Hours;
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48;
Change From Baseline in EQ-5D Scale Total Score- Utility Score;
Change From Baseline in CDR-SB Score at Weeks 12, 24 and 36;
Number of Participants With Change From Baseline in Vital Signs of Clinical Concern at Any Time on Treatment- Weight;
Change in CDR-SB Total Score for Observed Cases at Week 54 Compared to Week 48;
Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score;
Any Time on Treatment Differences in Frequencies of Hematology Data Outside the Reference Range;


________________________________________________________________
Riga 14 supera TOK_MAX (2957 > 1700) – saltata.

outcome_measurement_title:
Change in ADAS-Cog Total Score for Observed Cases at Week 54 Compared to Week 48;
Change From Baseline in ADAS-Cog Total Score for Observed Cases at Weeks 8, 16, 24, 36 and 48;
Change From Baseline in European Quality of Life-5 Dimensions Proxy Version (EQ-5D Proxy) Scale Total Score Assessed by Thermometer (Visual Analog Scale [VAS]) and Utility;
Change in CDR-SB Total Score at Week 54 Compared to Week 48;
Change From Baseline in CDR-SB Score for Observed Cases at Weeks 12, 24, 36 and 48;
Change From Screening in Mini Mental State Examination (MMSE) Total Score;
Change From Baseline in Hemoglobin Values;
Change From Baseline in Hematocrit Values;
Change From Baseline in the Domains of the Resource Utilization in Dementia Scale (RUD);
Mean Change From Baseline in Weight;
Change From Baseline in Alzheimer's Carer Quality of Life Instrument (ACQLI) Total Score;
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 48;
Mean Change From Baseline in Short Term Memory Assessment Score;
Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) at Week 48 for APOE E4;
Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score;
Change From Baseline in HbA1c at Week 12, Week 24 and Week 36;
Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP);
Number of Participants With Laboratory Potential Clinical Concern (PCC) Values;
Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score;
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs);
Mean Change From Baseline in Heart Rate;
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 48;


________________________________________________________________
Riga 23 supera TOK_MAX (4559 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline (W0) in Periodic HbA1c Assessment;
Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W24 as a Function of APOE e4 Status in APOE4 Negative Cohort;
Number of Par. With Clinical Chemistry Values of Potential Clinical Concern Any Time on Treatment;
Change From Baseline (W0) in Mean Disability Assessment for Dementia (DAD) Scale Total Score at W8, W16, W24;
Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in All Except e4/e4's Cohort;
Change From Baseline (W0) in Mean Short Term Memory Assessment Total Score (ADAS-Cog Q1 Plus Q7) at W8, W16, W24;
Change From Baseline (W0) in Hemoglobin;
Change From Baseline (W0) in Mini Mental State Examination (MMSE) Total Score at W24.;
Change From Baseline (W0) in Body Weight;
Change From Baseline (W0) in Mean European Quality of Life -5 Dimensions Proxy Version (EQ-5D Proxy) Total Score at W12, W24 Assessed by Utility;
Change From Baseline (W0) in Hematocrit;
Change From Baseline (W0) in Alzheimer's Carer's Quality of Life Instrument (ACQLI) Score at W12 and W24.;
Change From Baseline (W0) in Mean ADAS-Cog Total Score at W8, W16, W24;
Change From Baseline (W0) in 12-lead Electrocardiogram (ECG);
Number of Par. With Hematology Data of Potential Clinical Concern Any Time on Treatment;
Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Apolipoprotein epsilon4 (APOE e4) Negative Cohort;
Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W24 as a Function of APOE e4 Status in All Except e4/e4's Cohort;
Time Spent Caring for Basic and Instrumental Activities Resource Utilization in Dementia (RUD) Scale at W12 and W24;
Number of Participants With Systolic and Diastolic Blood Pressure (SBP and DBP), Heart Rate (HR) and Weight Values of Potential Clinical Concern (PCC) Any Time on Treatment (ATOT).;
Change From Baseline (W0) in Heart Rate (HR) Measured From 12-lead Electrocardiogram (ECG);
Change From Baseline (W0) in Mean ADAS-Cog Total Score at W24 as a Function of APOE e4 Status in Full Population Cohort;
Number of Participants With Adverse Events Defined by Severity;
Change From Baseline (W0) in Glycosylated Hemoglobin (HbA1c) at W24.;
Change From Baseline (W0) in Mean European Quality of Life -5 Dimensions Proxy Version (EQ-5D Proxy) Total Score at W12, W24 Assessed by Thermometer (Visual Analog Scale [VAS]);
Change From Baseline (W0) in Mean Neuropsychiatric Inventory (NPI) Total Score at W8, W16, W24;
Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W8, W16, W24;
Change From Baseline (W0) in Mean CIBIC+ Global Functioning Total Score at W24 as a Function of APOE e4 Status in Full Population Cohort;


________________________________________________________________
Riga 37 supera TOK_MAX (2345 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline in Vital Sign Heart Rate (HR);
Change From Baseline in Mini Mental State Examination (MMSE) Total Score as a Function of APOE ε4 Status.;
Change From Baseline in Vital Sign Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP);
Number of Participants With HR Values of PCC ATOT;
Number of Participants With SBP and DBP Values of Potential Clinical Concern (PCC);
Change From Baseline in Non-fasting Measures of Lipid Metabolism Namely Total Cholesterol (TC), High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), Triglycerides;
Change From Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score as a Function of APOE ε4 Status.;
Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score as a Function of APOE ε4 Status.;
Number of Participants With Hematology Parameters of PCC ATOT;
Number Participants With Serious Adverse Events (SAEs) and Deaths;
Number of Participants With Clinical Chemistry Parameters (Including Lipids) of PCC ATOT;
Number of Participants With Any Adverse Events (AEs) and Severity of AEs;
Number of Participants With Adverse Event of Oedema;
Change From Baseline in Vital Sign Body Weight (BW);
Number of Participants With BW Values of PCC ATOT;
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total Score as a Function of Apolipoprotein E (APOE) ε4 Status.;
Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score as a Function of APOE ε4 Status.;


________________________________________________________________
Riga 41 supera TOK_MAX (2536 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline in Mini Mental State Examination (MMSE) Total Score as a Function of APOE 4 Status at W24 and W52;
Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score as a Function of APOE 4 Status at W24 and W52;
Number of Participants With Clinical Chemistry Parameters of Potential Clinical Concern;
Change From Baseline in Heart Rate (HR);
Number of Participants With Abnormal HR at Any Time During Treatment Period;
Number of Participants With Serious AEs and Deaths;
Number of Participants With Any Adverse Events (AEs) and Severity of AEs;
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP);
Number of Participants With Abnormal BW at Any Time During Treatment Period;
Change From Baseline in Disability Assessment for Dementia Scale (DAD) Total Score as a Function of APOEe 4 Status;
Change From Baseline in Glycosylated Haemoglobin (HbA1c);
Mean Clinician Interview-Based Impression of Change Plus Caregiver Input (CIBIC+) Score as a Function of APOE 4 Status;
Number of Participants With Hematological Parameters of Potential Clinical Concern;
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) Total Score as a Function of Apolipoprotein E (APOE) 4 Status at W24 and W52;
Change From Baseline in Body Weight (BW);
Number of Participants With Abnormal SBP and DBP at Any Time During Treatment Period;
Percentage of Participants With AEs of Edema;
Change From Baseline in Non-fasting Measures of Lipid Metabolism Including Total Cholesterol, High Density Lipoprotein, Low Density Lipoprotein and Triglycerides at Indicated Timepoints.;


________________________________________________________________
Riga 54 supera TOK_MAX (2343 > 1700) – saltata.

outcome_measurement_title:
Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan);
Change From Baseline in Dependence Scale Total Score at Week 78;
Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan);
Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan);
Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan);
Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan);
Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78;
Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78;
Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan);
Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71;
Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis);
Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan);
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78;
Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78;
Divergence of Effect on the DAD Total Scores From Week 39 to Week 78;
Change From Baseline in Brain Amyloid Burden at Week 71;
Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71;


________________________________________________________________
Riga 56 supera TOK_MAX (6569 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline in RBANS Total Score at Week 12;
Change From Baseline in Hematology Parameter Mean Corpuscle Volume and Mean Platelet Volume at Week 24;
Number of Participants With Vital Signs Data of Potential Clinical Concern (PCC) Any Time on Treatment (ATOT);
Change From Baseline in Clinical Chemistry Parameters Alanine Amino Transferase, Alkaline Phosphatase, Aspartate Amino Transferase, Creatine Kinase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at Week 24;
Change From Baseline in Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Platelet Count, Segmented Neutrophils, Total Neutrophils, White Blood Cell Count at Week 24;
Change From Baseline in ADAS-Cog Total Score at Week 12;
Change From Baseline in Clinical Chemistry Parameter Blood Urea Nitrogen /Creatinine Ratio at Week 24;
CIBIC+ Score at Week 12;
Number of Participants With Electrocardiogram (ECG) Findings as Assessed by Investigator and Central Cardiologist;
Number of Participants With Any Adverse Event (Serious and Non-serious) and Serious Adverse Events (SAEs);
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 24;
Change From Baseline in Hematology Parameters Hemoglobin and Mean Corpuscle Hemoglobin Concentration at Week 24;
Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 10-20) on the CIBIC+ Score at Week 12;
Change From Baseline in ADCS-ADL-Basic Score; ADCS-ADL: Instrumental Score and ADCS-ADL: Total Independence Score at Weeks 12 and 24;
Change From Baseline in Clinical Chemistry Parameters Albumin and Total Protein at Week 24;
Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 16-26) on the CIBIC+ Score at Week 12;
Exposure Estimates for SB-742457 Area Under Curve Over the Dosing Interval at Steady State (AUCτss);
Change From Baseline in Clinical Chemistry Parameters Calcium, CO2 Content/Bicarbonate, Chloride, Glucose, HDL Cholesterol, LDL Cholesterol, Magnesium, Phosphorus, Potassium, Sodium, Triglycerides, Urea/Blood Urea Nitrogen at Week 24;
Change From Baseline in Clinical Chemistry Parameters Creatinine, Direct Bilirubin and Total Bilirubin at Week 24;
Change From Baseline in Cornell Scale for Depression in Dementia (CSDD) Total Score at Week 24;
Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 10-20) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 12;
Change From Baseline in Hematology Parameter Hematocrit;
Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline [MMSE Scores 10-20) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 24;
Number of Participants With Chemistry Data of PCC ATOT;
Exposure Estimates for SB-742457 Minimum Concentration at Steady State (Cmin-ss);
Exposure Estimates for Donepezil Average Concentration at Steady State (Cavgss);
Number of Participants With Hematology Data of PCC ATOT;
Clinician's Interview-Based Impression of Change - Plus (CIBIC+) Score at Week 24;
Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 10-20) on the CIBIC+ Score at Week 24;
Change From Baseline in MMSE Total Score at Week 24;
Change From Baseline in Hematology Parameter Mean Corpuscle Hemoglobin at Week 24;
Change From Baseline in Hematology Parameter Red Blood Cell Count at Week 24;
Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline Mini Mental State Examination [MMSE] Scores 16-26) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 24;
Change From Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Total Score at Weeks 12 and 24;
Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 16-26) on the Change From Baseline in ADAS-Cog Total Score, the Change From Baseline in RBANS Total Score at Week 12;
Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score at Week 24;
Effect of Baseline Severity (Including Subgroup Analyses Based on Baseline MMSE Scores 16-26) on the CIBIC+ Score at Week 24;


________________________________________________________________
Riga 57 supera TOK_MAX (2652 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline in ADAS-Cog Total Score at Week 12, 36 and 48;
Exposure Estimates for Donepezil (Cavgss);
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During Treatment Phase;
Change From Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score at Week 24;
Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Score at Week 24;
Change From Baseline in RBANS Scale in Participants With APOE4 Gene;
Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Week 24 and 48;
Number of Participants With Parameters of Clinical Concern - Hematology;
Change From Baseline in ADAS-Cog Scale in Participants With APOE4 Gene;
Exposure Estimates for SB-742457 : Area Under the Concentration Time Curve Over the Dosing Interval at Steady State (AUCτss);
Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Total Score at Week 24;
Change From Baseline in RBANS Score at Week 12, 36 and 48;
Change From Baseline in Alzheimer's Disease Co-operative Study Group - Activities of Daily Living Inventory (ADCS- ADL) Total Score at Weeks 12, 24, 36 and 48;
Number of Participants With Parameters of Clinical Concern - Clinical Chemistry;
Change From Baseline in CDR-SB Score at Week 12, 36 and 48;
Change From Baseline in CDR-SB Scale in Participants With APOE4 Gene;
Exposure Estimates for SB-742457 : Minimum Concentrations at Steady State (Cmin-ss);


________________________________________________________________
Riga 67 supera TOK_MAX (2332 > 1700) – saltata.

outcome_measurement_title:
Change in Cognitive Tests-Time to Perform TMT in MC and CNE Groups;
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to the DSM IV (Diagnostic of Dementia);
Change in Brain Glucose Metabolism in the MC and CNE Groups;
Change in Cognitive Tests-Cube Drawing Test Score in MC and CNE Groups;
Incidence of Adverse Events (AEs);
Change in Cognitive Tests-Clock Drawing Test Score in MC and CNE Groups;
Change in Cognitive Tests-Verbal Fluency in MC and CNE Groups;
Change in Cognitive Tests-MMSE Score in MC and CNE Groups;
Change in Cognitive Tests-Clinical Dementia Rating (CDR) Score in MC and CNE Groups;
Change in Cognitive Tests-Mini Mental Status Examination (MMSE) Score in MC and CNE Groups;
Change in Cognitive Tests-Geriatric Depression Scale (GDS) Score in MC and CNE Groups;
Change in Cognitive Tests-GDS Score in MC and CNE Groups;
Change in Brain Glucose Metabolism Measured Using 18-Fluorodeoxyglucose Positron Emission Tomography (18FDG-PET);
Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of FCSRT;
Change in Cognitive Tests-Age-Adjusted Wechsler Adult Intelligence Scale (WAIS) in MC and CNE Groups;
Change in Cognitive Tests-Age-Adjusted WAIS in MC and CNE Groups;
Change in Cognitive Tests in MC and CNE Groups - Total Immediate Recall and Delayed Recall Scores of the Free and Cued Selective Reminding Test (FCSRT);
Change in Cognitive Tests-Time to Perform Trail Making Test (TMT) in MC and CNE Groups;
Change in Cognitive Tests-Age-Adjusted Logical Memory (MEM III) in MC and CNE Groups;
Change in Brain Morphology in the MC and CNE Groups as Determined by the Change in Voxel Size;
Number of Subjects Conversion to Alzheimer's Dementia Diagnosed According to NINCDS-ADRDA (Diagnostic of Alzheimer's);
Change in Cognitive Tests-CDR Score in MC and CNE Groups;


________________________________________________________________
Riga 69 supera TOK_MAX (2229 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Backward;
Change From Baseline at 9 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL);
Number of Participants Experiencing Any Serious Adverse Events (SAEs), by System Organ Class;
Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Participant Response;
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: FAS Verbal Fluency;
Change From Baseline at 18 Months in the Neuropsychiatric Inventory (NPI) Assessment;
Number of Participants Experiencing a Clinically Significant Rash;
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Symbol Substitution;
Change From Baseline at 9 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog);
Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog);
Number of Participants Experiencing Any Non-serious Adverse Events (Non-SAEs), by System Organ Class;
Change From Baseline at 9 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment;
Change From Baseline at 18 Months in the Modified Mini-Mental State Examination (3MS) Examination;
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Wechsler Adult Intelligence Scale- Revised (WAIS-R) Digit Span Forward;
Change From Baseline at 18 Months in Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Assessment;
Change From Baseline at 18 Months in the Logsdon Quality of Life in Alzheimer's Disease (QOL-AD) Assessment- Caregiver Response;
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part A;
Number of Infusions Temporally Associated With Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs);
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Animals Category Fluency;
Change From Baseline at 18 Months in Alzheimer´s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL);
Number of Infusions With Causally Associated Non-serious Adverse Events (Non-SAEs) and/or Serious Adverse Events (SAEs);
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Trail-Making Test (TMT), Part B;
Change From Baseline at 18 Months in the Adjunct Neuropsychological Testing: Clock Drawing Test;


________________________________________________________________
Riga 71 supera TOK_MAX (4675 > 1700) – saltata.

outcome_measurement_title:
All Subjects Improved/Stabilized or Worsened for Mood in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
All Subjects Improved/Stabilized or Worsened for Repetitiveness in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
All Subjects Improved/Stabilized or Worsened for Asphasia in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
Change From Baseline in Subject's Mobility at Week 12 LOCF;
All Subjects Improved/Stabilized or Worsened for Insight in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
Change From Baseline in Subject's Pain/Discomfort at Week 12;
Correlation Between Change From Baseline in Mini-Mental State Examination (MMSE) Score and Change From Baseline in Combined Patient and Caregiver Health Related Quality of Life (Alzheimer's Disease) (HR QoL-AD) Questionnaire Total Score;
All Subjects Improved/Stabilized or Worsened for Domestic Activities in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
Last Observation Carried Forward (LOCF) Change From Baseline in Mini-Mental State Examination (MMSE) Total Scores at Week 12;
Correlation Between LOCF Change From Baseline in Mini-Mental State Examination (MMSE) Score and LOCF Change From Baseline in Combined Patient and Caregiver Health Related Quality of Life (Alzheimer's Disease) (HR QoL-AD) Questionnaire Total Score;
All Subjects Improved/Stabilized or Worsened for Delusions in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
LOCF Change From Baseline in Combined Patient and Caregiver Health Related Quality of Life (Alzheimer's Disease) (HR QoL-AD) Questionnaire Total Scores;
Correlation Analysis: LOCF Change From Baseline in Combined Patient and Caregiver Quality of Life in Alzheimer's Disease (QoL-AD) Questionnaire Total Score Versus the Number of Treatment Emergent Adverse Events (TEAEs);
Change From Baseline in Subject's Usual Activities at Week 12 LOCF;
All Subjects Improved/Stabilized or Worsened for Severity in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
All Subjects Improved/Stabilized or Worsened for Remembering in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
All Subjects Improved/Stabilized or Worsened for Telephoning in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
Change From Baseline in Subject's Pain/Discomfort at Week 12 LOCF;
All Subjects Improved/Stabilized or Worsened for Anxiety in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
Change From Baseline in Mini-Mental State Examination (MMSE) Total Scores at Week 12;
All Subjects Improved/Stabilized or Worsened for Spatial Orientation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
All Subjects Improved/Stabilized or Worsened for Agitation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
Change From Baseline in Subject's Self-Care at Week 12;
Change From Baseline in Subject's Mobility at Week 12;
Change From Baseline in Visual Analog Scale (VAS) of Subject's Overall Health Included in EuroQuality of Life-5 Domains (EQoL-5D)Questionnaire;
All Subjects Improved/Stabilized or Worsened for Attention in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
Change From Baseline in Subject's Self-Care at Week 12 LOCF;
All Subjects Improved/Stabilized or Worsened for Caregiver in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
All Subjects Improved/Stabilized or Worsened for Dressing in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
Change From Baseline in Subject's Usual Activities at Week 12;
All Subjects Improved/Stabilized or Worsened for Judgment in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
All Subjects Improved/Stabilized or Worsened for Cognitive Activation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
All Subjects Improved/Stabilized or Worsened for Apathy in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
All Subjects Improved/Stabilized or Worsened for Leisure in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
All Subjects Improved/Stabilized or Worsened for Hygiene in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
Change From Baseline Total Score in EuroQuality of Life-5 Domains (EQoL-5D);
Correlation Analysis: Change From Baseline in Combined Patient and Caregiver Quality of Life in Alzheimer's Disease(QoL-AD) Questionnaire Total Score Versus Number of Treatment Emergent Adverse Events (TEAEs);
LOCF Change From Baseline in Visual Analog Scale (VAS) of Subject's Overall Health Included in EuroQuality of Life-5 Domains (EQoL-5D) Questionnaire;
Change From Baseline in Combined Patient and Caregiver Health Related Quality of Life (Alzheimer's Disease) (HR QoL-AD) Questionnaire Total Scores;
All Subjects Improved/Stabilized or Worsened for Temporal Orientation in Top Symptom Checklist (TOPS) Alzheimer's Disease Assessment;
Change From Baseline in Subject's Anxiety/Depression at Week 12;
LOCF Change From Baseline Total Score in EuroQuality of Life-5 Domains (EQoL-5D);
Change From Baseline in Subject's Anxiety/Depression at Week 12 LOCF;


________________________________________________________________
Riga 79 supera TOK_MAX (2813 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) Total Score at Week 24;
Change From Baseline in CANTAB SWM Strategy at Week 24;
Change From Baseline in CANTAB RTI Five-Choice Reaction Time at Week 24;
Change From Baseline in CANTAB Reaction Time (RTI) Five-Choice Accuracy at Week 24;
Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associate Learning (PAL)Total Errors (N, Shapes, Adjusted) at Week 24;
Change From Baseline in CANTAB SWM - Between Errors (N Boxes) at Week 24;
Percentage of Participants Who Were Responders at Week 24;
Change From Baseline in CANTAB RTI Five-Choice Movement Time at Week 24;
Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 24;
Change From Baseline in CANTAB-SWM - Between Errors (6 Boxes) at Week 24;
Change From Baseline in Neuropsychiatry Inventory (NPI) at Week 24;
Change From Baseline in CANTAB SWM - Between Errors (8 Boxes) at Week 24;
Change From Baseline in CANTAB Spatial Working Memory (SWM) - Between Errors (4 Boxes) at Week 24;
Change From Baseline in CANTAB PAL - Number of Patterns Reached at Week 24;
Change From Baseline in CANTAB RTI Simple Movement Time at Week 24;
Change From Baseline in CANTAB PAL - First Trial Memory Score, Patterns at Week 24;
Number of Participants With Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) Scores at Week 24;
Change From Baseline in CANTAB Pattern Recognition Memory (PRM)-Mean Correct Latency at Week 24;
Change From Baseline in CANTAB PRM-Percentage Correct at Week 24;
Change From Baseline in CANTAB RTI Simple Reaction Time at Week 24;


________________________________________________________________
Riga 112 supera TOK_MAX (2289 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline to 104-week Endpoint in Alzheimer's Disease Assessment Scale - Cognitive Subscore 11-Item Scale (ADAS-Cog11);
Change From Baseline to 104-week Endpoint in Mini-Mental State Examination (MMSE);
Change From Baseline to 104-week Endpoint in Volumetric Magnetic Resonance Imaging (vMRI);
Change From Baseline to 104-week Endpoint in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL);
Change From Baseline to 104-week Endpoint in Quality of Life in Alzheimer's Disease (QoL-AD);
Change From Baseline to 104-week Endpoint in Neuropsychiatric Inventory (NPI);
Change From Baseline to 104-week Endpoint in Clinical Dementia Rating - Sum of Boxes (CDR-SB);
Change From Baseline to 52-week Endpoint in Plasma Amyloid Beta (Aβ) Levels;
Mean Change From Baseline to Endpoint in Amyloid Imaging Parameters in Subjects With Mild Alzheimer's Disease;
Assess the Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs);
Change From Baseline to 104-week Endpoint in Resource Utilization in Dementia - Lite (RUD-Lite) Caregiver Hours;
Change From Baseline to 104-week Endpoint in EuroQol 5-Dimensional Health-Related Quality of Life Scale Proxy Version (EQ-5D Proxy);
Change From Baseline to 104-week Endpoint in Alzheimer's Disease Assessment Scale - Cognitive 14-Item Scale (ADAS-Cog14);


________________________________________________________________
Riga 122 supera TOK_MAX (2273 > 1700) – saltata.

outcome_measurement_title:
Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 104 (Double-Blind Treatment Phase);
Mean Change From Baseline in CDR-Global Score at Week 104 (Double-Blind Treatment Phase);
Percentage Change From Baseline in Cerebrospinal Fluid Biomarkers (Phosphorylated-tau [P-tau], Amyloid Beta 1-42 [Abeta 1-42], Total Tau [T-tau]) at Week 104 (Double-Blind Treatment Phase);
Percentage Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 (Double-Blind Treatment Phase);
Percentage Change From Baseline in Cortical Composite Sustained Uptake Volume Ratio (SUVr) in Different Brain Regions at Week 156 (OLE Phase);
Percentage of Participants With Anti-Drug Antibodies (ADAs) (OLE Phase);
Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 13 (ADAS-Cog-13) Scores at Week 156 (OLE Phase);
Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) (Double-Blind Treatment Phase);
Percentage of Participants With Anti-Drug Antibodies (ADAs) (Double-Blind Treatment Phase);
Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104 (Double-Blind Treatment Phase);
Gantenerumab Plasma Concentrations at Different Time Points (Double-Blind Treatment Phase);
Mean Change From Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 156 (OLE Phase);
Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 104 (Double-Blind Treatment Phase);
Mean Change From Baseline in Free and Cued Selective Reminding Test (FCSRT) Score at Week 104 (Double-Blind Treatment Phase);
Mean Change From Baseline in Functional Activities Questionnaire (FAQ) Score at Week 156 (OLE Phase);
Time to Onset of Dementia at Week 104 (Double-Blind Treatment Phase);
Mean Change From Baseline in Cambridge Neuropsychological Test Automated Battery (CANTAB) Composite Score at Week 104 (Double-Blind Treatment Phase);
Percentage Change From Baseline in Hippocampal Volume at Week 152 (OLE Phase);
Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 156 (OLE Phase);
Mean Change From Baseline in Mini Mental State Exam (MMSE) Score at Week 104 (Double-Blind Treatment Phase);
Mean Change From Baseline in CDR-Global Score at Week 156 (OLE Phase);
Percentage Change From Baseline in Hippocampal Volume at Week 104 (Double-Blind Treatment Phase);
Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 156 (OLE Phase);
Time to Onset of Dementia at Week 156 (OLE Phase);
Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs) (OLE Phase);
Gantenerumab Plasma Concentrations at Different Time Points (OLE Phase);
Mean Change From Baseline in Neuropsychiatric Inventory (NPI) Questionnaire Score at Week 104 (Double-Blind Treatment Phase);
Mean Change From Baseline in Alzheimer Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog-11) Scores at Week 156 (OLE Phase);


________________________________________________________________
Riga 124 supera TOK_MAX (4615 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline in PDQ - Subject - Prospective Memory Domain Score;
Change From Baseline in Volumetric Brain MRI Measurements in Ventricular Boundary Shift Integral (VBSI);
Alzheimer's Disease Medication Administration Concerns Questionnaire (AD MACQ);
Geometric Mean Anti-Aβ IgG Enzyme-linked Immunosorbent Assay (ELISA) Titers;
Percentage of Participants With a Global CDR Score of Equal to or Greater Than 1 for the First Time;
Change From Baseline in Mini Mental State Examination (MMSE) Total Score;
Geometric Mean Anti-Aβ IgM ELISA Titers;
Change From Baseline in Neuropsychological Test Battery (NTB);
Change From Baseline in PDQ-R - Relative - Prospective Memory Domain Score;
Change From Baseline in Volumetric Brain MRI Measurements in HBSI, Left;
Change From Baseline in PDQ - Subject - Total Score;
Change From Baseline in PDQ-R - Relative - Retrospective Memory Domain Score;
Change From Baseline in PDQ - Subject - Planning/Organization Domain Score;
Change From Baseline in Volumetric Brain MRI Measurements in HBSI, Right;
Change From Baseline in Cerebrospinal Fluid (CSF) Aβ x-40;
Change From Baseline in NPI Distress Score (NPI-D);
Change From Baseline in Volumetric Brain Magnetic Resonance Imaging (MRI) Measurements in Brain Boundary Shift Integral (BBSI);
Change From Baseline in CSF p-Tau;
Change From Baseline in PDQ - Subject - Retrospective Memory Domain Score;
Change From Baseline in PDQ-R - Relative - Planning/Organization Domain Score;
Change From Baseline in Plasma Aβ x-40;
Change From Baseline in Volumetric Brain MRI Measurements in Hippocampal Boundary Shift Integral (HBSI), Total;
Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ) at Week 104 as Measured by Standard Uptake Value Ratios (SUVRs) Over the Composite Regions of Interest (ROIs);
Change From Baseline in Perceived Deficits Questionnaire (PDQ) - Subject - Attention/Concentration Domain Score;
Change From Baseline in PDQ-R - Relative - Attention/Concentration Domain Score;
Change From Baseline in Resource Utilization in Dementia (RUD) (Abbreviated) (RUD-Lite) - Primary Caregiver;
Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score;
Change From Baseline in 13-item Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) Total Score;
Change From Baseline in RUD (Abbreviated) (RUD-Lite) - Other Caregivers;
Change From Baseline in CSF Total Tau;
Change From Baseline in Dependence Scale (DS) Score;
Change From Baseline in Functional Activities Questionnaire (FAQ) Total Score;
Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB);
Change From Baseline in PDQ-R - Relative - Total Score;
Change From Baseline in CSF Aβ x-42;


________________________________________________________________
Riga 140 supera TOK_MAX (3529 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline in NPI Individual Item Scores in Acute Phase: Agitation/Aggression;
Change From Baseline in Brief Psychiatric Rating Scale (BPRS) Total Score in Acute Phase;
Change From Baseline in Clinical Global Impression (CGI) Severity of Illness Score in Acute Phase;
Participants With Potentially Clinically Significant Laboratory Abnormalities During Extension Phase;
Participants Who Demonstrated a ≥ 50% Decrease From Baseline to Endpoint in the NPI Psychosis Subscale Score in Acute Phase;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Elation/Euphoria;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Disinhibition;
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score in Acute Phase;
Change From Baseline in Barnes Global Clinical Assessment of Akathisia in Acute Phase;
Change From Baseline in Simpson-Angus Scale (SAS) Total Score in Acute Phase;
Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AE During Extension Phase;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Delusions;
Participants Who Demonstrated a ≥ 50% Decrease From Baseline in the Total NPI Score in Acute Phase;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Sleep;
Participants With a Potentially Clinically Significant Electrocardiogram Abnormalities During Extension Phase;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Aberrant Motor Behavior;
Change in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score From Baseline During Extension Phase;
Participants With Extrapyramidal Symptoms (EPS) Related Adverse Events in Acute Phase;
Change From Baseline in NPI Psychosis Subscale Score Through Week 8 in Acute Phase;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Depression/Dysphoria;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Anxiety;
Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AEs in Acute Phase;
Change From Baseline in NPI Total Caregiver Distress Score in Acute Phase;
Participants Who Died, Experienced Serious Adverse Events (SAEs), Adverse Events (AEs) or Discontinuations Due to AE During Treatment Beyond 140 Weeks;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Apathy/Indifference;
Participants With Potentially Clinically Significant Electrocardiogram Abnormalities in Acute Phase;
Change in Abnormal Involuntary Movement Scale (AIMS) Total Score During Extension Phase;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Irritability/Lability;
CGI Improvement Score in Acute Phase;
Change From Baseline in Mini Mental State Examination (MMSE) Total Score in Acute Phase;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Appetite/Eating Behaviors;
Participants With Potentially Clinically Significant Laboratory Abnormalities in Acute Phase;
Change From Baseline in NPI Total Score in Acute Phase;
Change From Baseline in NPI Individual Item Scores in Acute Phase: Hallucinations;
Participants With a Potentially Clinically Significant Vital Sign Abnormality During Extension Phase;
Change in Simpson-Angus Scale (SAS) Total Score During Extension Phase;
Participants With Extrapyramidal Symptoms (EPS) Related Adverse Events During Extension Phase;
Participants With Potentially Clinically Significant (PCS) Vital Sign Abnormalities in Acute Phase;
Change From Baseline in Neuropsychiatric Inventory (NPI) Psychosis Subscale Score at Week 10 in Acute Phase;
Change in Barnes Global Clinical Assessment of Akathisia Score During Extension Phase;
Change From Baseline in NPI Psychosis Subscale Caregiver Distress Score in Acute Phase;
Clinical Global Impression (CGI) Improvement Score During Extension Phase;


________________________________________________________________
Riga 159 supera TOK_MAX (4307 > 1700) – saltata.

outcome_measurement_title:
Number of Participants With the Indicated Response on the mADCS-CGIC Scale Agitation Domain at Day 70 Compared to Their Response at Day 36 (Stage 2 Baseline);
Number of Participants Using Rescue Medications;
Number of Participants With the Indicated Categorical Response on the Patient Global Impression of Change (PGI-C) for the Caregiver Domain at Day 36 (Stage 2 Baseline) and Day 70 Compared to Their Response at Day 1 (Stage 1 Baseline);
Change in the NPI-CDS NPI4D Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Change in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Change in the Mini-Mental State Examination (MMSE) Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline), as Analyzed by the Specified SPCD Methodology;
Change in the Caregiver Strain Index (CSI) Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Change in the Quality of Life-Alzheimer's Disease (QoL-AD) Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Change in the Sum of the Agitation/Aggression, Irritability/Lability, Anxiety, and Aberrant Motor Behavior NPI Domain (NPI4A) Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Change in the Cornell Scale for Depression in Dementia (CSDD) Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Number of Participants With the Indicated Response on the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change Rating (mADCS-CGIC) Scale Agitation Domain at Day 36 and Day 70 Compared to Their Response at Day 1 (Stage 1 Baseline);
Change in the Individual NPI Domain Scores From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Change in the NPI-CDS for the Agitation/Aggression Domain From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Number of Participants With the Indicated Categorical Response on the PGI-C for the Caregiver Domain at Day 70 Compared to Their Response at Day 1 (Stage 1 Baseline);
Change in the NPI Agitation/Aggression Domain Score From Day 1 (Stage 1 Baseline) to Day 8 and Day 22 and From Day 36 (Stage 2 Baseline) to Day 43 and Day 57;
Change in the NPI-CDS NPI4A Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Change in the Total NPI Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Change in the Total Neuropsychiatric Inventory-Caregiver Distress Score (NPI-CDS) From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Change in the Sum of the Agitation/Aggression, Irritability/Lability, Disinhibition, and Aberrant Motor Behavior NPI Domain (NPI4D) Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;
Number of Participants With the Indicated Change in the Concomitant Use of Allowed Psychotropic Drugs Compared to Their Baseline Use;
Number of Participants With the Indicated Type of Adverse Event;
Change in the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL) Score From Day 1 (Stage 1 Baseline) to Day 36 (Stage 2 Baseline) and From Day 36 to Day 70;


________________________________________________________________
Riga 174 supera TOK_MAX (2732 > 1700) – saltata.

outcome_measurement_title:
[Part I (Base Study)] Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score;
[Part I (Base Study)] Percentage of Participants Achieving Responder Status;
[Part I (Base Study)] Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score;
[Part II (Extension Study)] Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score;
[Part II (Extension Study)] Number of Participants Who Discontinued From Study Drug Due to an Adverse Event;
[Part I (Base Study)] Percent Change From Baseline in Total Hippocampal Volume (THV);
[Part I (Base Study)] Number of Participants Who Experienced an Adverse Event;
[Part I (Base Study)] Change From Baseline in Mini-Mental State Examination (MMSE) Score;
[Part I (Base Study)] Number of Participants Who Discontinued From Study Drug Due to an Adverse Event;
[Part I (Base Study)] Change From Baseline in Neuropsychiatric Inventory (NPI) Score;
[Part I (Base Study)] Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score;
[Part II (Extension Study)] Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score;
[Part II (Extension Study)] Number of Participants Who Experienced an Adverse Event;
[Part I (Base Study)] Fold Change From Baseline in Cerebrospinal Fluid (CSF) Total Tau;
[Part I (Base Study)] Change From Baseline in Cortical Amyloid Load Assessed by [18F]Flutemetamol PET Standard Uptake Value Ratio (SUVR);


________________________________________________________________
Riga 186 supera TOK_MAX (3223 > 1700) – saltata.

outcome_measurement_title:
Period A: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);
Period A: Annualized Rate of Change in an Episodic Memory Measure: Free and Cued Selective Reminding Task (FCSRT) Cueing Index;
Period A: Annualized Rate of Change in a Measure of Overall Neurocognitive Functioning: RBANS;
Period A: Time to Progression From Preclinical AD to Mild Cognitive Impairment (MCI) Due to AD or From Preclinical AD to Dementia Due to AD;
Period A: Annualized Rate of Change in Regional Cerebral Metabolic Rate of Glucose (CMRgI) Using Fluorine-18-Labeled 2-Deoxyglucose (FDG)-PET in a Predefined ROI;
Period A: Annualized Rate of Change in the CDR Scale - Sum of Boxes (SOB);
Period A: Time to Progression to Non-zero in CDR Scale Global Score;
Period A: Number of Participants With Adverse Events of Special Interest (AESIs);
Period A: Number of Participants Who Withdrew From the Study Treatment Due to AEs;
Period B: Number of Participants Who Withdraw From the Study Treatment Due to AEs;
Period A: Annualized Rate of Change in Mean Cerebral Fibrillar Amyloid Accumulation Using Florbetapir Positron Emission Tomography (PET);
Period A: Number of Participants With Anti-Crenezumab Antibodies;
Period A: Annualized Rate of Change in Plasma Concentrations of Amyloid Beta 1(Aβ1)-40 and Amyloid Peptide Beta 42 (Aβ1-42);
Period B: Number of Participants With Injection Reactions and IRRs;
Period A: Number of Participants Injection Reactions and Infusion-related Reaction (IRRs);
Period B: Number of Participants With AESIs: ARIA-E, ARIA-H, Cerebral Macrohemorrhages, and Pneumonia;
Period A: Annualized Rate of Change in Tau-Based Cerebral Spinal Fluid (CSF) Biomarkers (Total Tau (tTau) and Phospho-tau (pTau);
Period A: Annualized Rate of Change in Brain Atrophy Measured by Volumetric Measurements Using Magnetic Resonance Imaging (MRI);
Period A: Annualized Rate of Change in the Autosomal-Dominant Alzheimer's Disease (API ADAD) Composite Cognitive Test Total Score;
Period B: Number of Participants With AEs and SAEs;


________________________________________________________________
Riga 210 supera TOK_MAX (2510 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline on the Mini-Mental State Examination (MMSE);
Change From Baseline in CSF Phosphorylated Tau;
Change From Baseline in Brain Amyloid Burden Using Florbetapir Amyloid Positron Emission Tomography (PET) Scan;
Change From Baseline in Whole Brain Volume;
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score;
Change From Baseline in Tau PET ((Flortaucipir F18);
Change From Baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13);
Change From Baseline on the Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory Instrumental Items (ADCS-iADL);
Change From Baseline in Brain Metabolism Using Fluorodeoxyglucose (FDG);
Change From Baseline in CSF Total Tau;
PD: Percent Change From Baseline in Concentration of CSF Biomarker Aβ1-40;
Change From Baseline on the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score;
Time to Progression as Measured by Loss of Clinical Dementia Rating (CDR) Global Score Stage;
Change From Baseline in Neuropsychiatric Inventory (NPI) Score;
Pharmacodynamics (PD): Percent Change From Baseline in Concentration of Cerebrospinal Fluid (CSF) Biomarker Amyloid Beta (Aβ)1-42;
Change From Baseline on the Functional Activities Questionnaire (FAQ) Score;


________________________________________________________________
Riga 220 supera TOK_MAX (4691 > 1700) – saltata.

outcome_measurement_title:
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Standard Deviation (SUV StdDev) From Normal Patients in SUVr Values for Posterior Cingulate Gyrus Region of Brain;
Neurocognitive Function - QUALID- 6 Months Change From Baseline;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Ratio (SUVr) for Parietal Region of the Brain Compared to Cerebellum;
Common Terminology Toxicity Criteria (Version 5.0) - 6 Months;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Standard Deviation (SUV StdDev) From Normal Patients in SUVr Values for Anterior Cingulate Gyrus Region of the Brain;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Standard Deviation (SUV StdDev) From Normal Patients in SUVr Values for Frontal Region of the Brain;
Common Terminology Toxicity Criteria (Version 5.0) - 12 Months;
Neurocognitive Function - QUALID- 3 Months Change From Baseline;
Neurocognitive Function - ADAS-Cog - 3 Months Change From Baseline;
Neurocognitive Function - QUALID- 6 Weeks Change From Baseline;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Ratio (SUVr) for Frontal Region of the Brain Compared to Cerebellum;
Neurocognitive Function - MMSE (Mini Mental Status Exam) 6 Weeks Change From Baseline;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Ratio (SUVr) for Posterior Cingulate Gyrus Region of the Brain Compared to Cerebellum;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Standard Deviation (SUV StdDev) From Normal Patients in SUVr Values for Parietal Region of the Brain;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Standard Deviation (SUV StdDev) From Normal Patients in SUVr Values for Precuneus Region of the Brain;
Neurocognitive Function - MMSE (Mini Mental Status Exam) 6 Months Change From Baseline;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Ratio (SUVr) for Whole Brain Cortex Compared to Cerebellum;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Ratio (SUVr) for Precuneus Region of the Brain Compared to Cerebellum;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change in "Positive" or "Negative" Determination;
Neurocognitive Function - MMSE (Mini Mental Status Exam) 3 Months Change From Baseline;
Common Terminology Toxicity Criteria (CTCAE) Version 5.0 - 3 Months;
Common Terminology Toxicity Criteria for Adverse Events (CTCAE) Version 5.0 - 6 Weeks;
Florbetaben F 18 Injection (AMYVID) Positron Emission Tomography (PET) Scan: Change From Baseline to 4 Months in Standardized Uptake Value Ratio (SUVr) for Anterior Cingulate Gyrus Region of the Brain Compared to Cerebellum;
Neurocognitive Function - QOL-AD - 3 Months Change From Baseline;
Neurocognitive Function - QOL-AD - 6 Months Change From Baseline;
Neurocognitive Function - QOL-AD - 6 Weeks Change From Baseline


________________________________________________________________
Riga 221 supera TOK_MAX (3452 > 1700) – saltata.

outcome_measurement_title:
898555185 - NA: Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels;
898555193 - NA: Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels;
898555201 - NA: Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels;
898555209 - NA: Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels;
Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Amyloid Beta (ABeta) (1-37, 1-38, 1-40, 1-42) Levels;
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs;
898555233 - NA: Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Plasma Amyloid Beta (ABeta) (1-38, 1-40, 1-42) Levels;
Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Plasma Amyloid Beta (ABeta) (1-38, 1-40, 1-42) Levels;
898555264 - NA: Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Tau Protein and Phosphorylated Tau (p-Tau) Protein Level;
898555272 - NA: Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Tau Protein and Phosphorylated Tau (p-Tau) Protein Level;
Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Tau Protein and Phosphorylated Tau (p-Tau) Protein Level;
898555217 - NA: Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Soluble Amyloid Precursor Protein (sAPP) Fragments (sAPP-alpha and sAPP-beta) Levels;
898555225 - NA: Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Soluble Amyloid Precursor Protein (sAPP) Fragments (sAPP-alpha and sAPP-beta) Levels;
Double-blind Treatment Phase (Period 1): Percent Change From Baseline in Cerebrospinal Fluid (CSF) Soluble Amyloid Precursor Protein (sAPP) Fragments (sAPP-alpha and sAPP-beta) Levels;


________________________________________________________________
Riga 224 supera TOK_MAX (3995 > 1700) – saltata.

outcome_measurement_title:
Stage 1: Resource Utilization in Dementia (RUD): Percentage of Caregiver Who Reported That Their Responsibilities Affected Their Work and Who Visited Health Care Professionals;
Stage 1 and Stage 2: Patient Global Impression of Change (PGIC) Score at Week 6 and Week 12;
Stage 1 and Stage 2: Change From Baseline in the NPI Caregiver Distress Score to Week 6 and Week 12;
Least Squares Mean Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation Score at Week 6 and Week 12;
Stage 2: Resource Utilization in Dementia (RUD): Percentage of Caregiver Who Reported That Their Responsibilities Affected Their Work and Who Visited Health Care Professionals;
Stage 1 and Stage 2: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score to Week 6 and Week 12;
Stage 1 and Stage 2: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Rating at Week 6 and Week 12;
Stage 1 and Stage 2: Change From Baseline in the NPI Total Score to Week 6 and Week 12;
Stage 1 and Stage 2: Change From Baseline in the NPI Irritability/Lability Domain Score to Week 6 and Week 12;
Stage 1: Resource Utilization in Dementia (RUD): Number of Hours Per Day the Caregiver Spent Assisting the Participant;
Stage 1 and Stage 2: Change From Baseline in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score to Week 6 and Week 12;
Stage 1 and Stage 2: Change From Baseline in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score to Week 6 and Week 12;
Stage 1 and Stage 2: Change From Baseline in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score to Week 6 and Week 12;
Stage 2: Resource Utilization in Dementia (RUD): Number of Hours Per Day the Caregiver Spent Assisting the Participant;
Stage 1 and Stage 2: Change From Baseline in the NPI Aberrant Motor Behavior Domain Score to Week 6 and Week 12;
Stage 2: Percentage of Participants With General Medical Health Rating (GMHR) Score;
12-Week Parallel Group: Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant;
Stage 1 and Stage 2: Change From Baseline in the Dementia Quality of Life (DEMQOL) Score to Week 6 and Week 12;
Stage 1: Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant;
Stage 1 and Stage 2: Change From Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score to Week 6 and Week 12;
Stage 1 and Stage 2: Change From Baseline in the Zarit Burden Interview (ZBI) Score to Week 6 and Week 12;


________________________________________________________________
Riga 225 supera TOK_MAX (2997 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline to Week 12 in the Patient Global Impression of Change (PGIC) Score;
Change From Baseline to Week 12 in the Clinical Global Impression of Severity of Illness (CGIS)-Agitation Domain Score;
Change From Baseline to Week 12 in the NPI Total Score;
Resource Utilization in Dementia (RUD) Score: Number of Days the Caregiver Spent Assisting the Participant;
Change From Baseline to Week 12 in the NPI Aberrant Motor Behavior Domain Score;
Change From Baseline to Week 12 in the Dementia Quality of Life (DEMQOL) Score;
Change From Baseline to Week 12 in the NPI Irritability/Lability Domain Score;
Change From Baseline to Week 12 in the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) Overall Rating;
Relative Change From Baseline to Week 12 in the Modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC)-Agitation Score;
Resource Utilization in Dementia (RUD) Score: Number of Visits to Hospital, Emergency, and Healthcare Professional;
Change From Baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) Composite Score;
Change From Baseline to Week 12 in the Zarit Burden Interview (ZBI) Score;
Change From Baseline to Week 12 in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Score;
Number of Participants With the Change From Baseline in the General Medical Health Rating (GMHR) Score at Week 12;
Change From Baseline to Week 12 in the Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score;
Change From Baseline in the Cornell Scale for Depression in Dementia (CSDD) Score;
Resource Utilization in Dementia (RUD) Score: Number of Hours Per Day the Caregiver Spent Assisting the Participant;
Change From Baseline to Week 12 in the NPI Agitation/Aggression Caregiver Distress Score;


________________________________________________________________
Riga 245 supera TOK_MAX (3039 > 1700) – saltata.

outcome_measurement_title:
EQ-5D Questionnaire Domain Score for Caregivers;
Change From Baseline to Week 105 on Cognition, as Assessed by Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) (Subscale) 13 (ADAS-Cog-13);
Change From Baseline to Week 105 on Severity of Dementia, Assessed Using the Mini Mental State Evaluation (MMSE);
Plasma Amyloid Beta (Abeta) 42 Concentrations;
Quality of Life-Alzheimer's Disease (QoL-AD) Scale Score;
Percentage of Participants With Adverse Event (AEs) and Serious Adverse Event (SAEs);
Change From Baseline to Week 105 on Function as Assessed by the ADCS-ADL Total Score;
Percentage of Participants With Anti-Crenezumab Antibodies;
Change From Baseline to Week 105 on Severity of Dementia, Assessed Using the CDR-Global Score (CDR-GS);
Plasma Amyloid Beta (Abeta) 40 Concentrations;
Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) Scale Score;
Percentage Change From Baseline to Week 105 in Whole Brain Volume as Determined by Magnetic Resonance Imaging (MRI);
Percentage Change From Baseline to Week 105 in Ventricle Volume as Determined by Magnetic Resonance Imaging (MRI);
Change From Baseline to Week 105 Assessed Using the Neuropsychiatric Inventory Questionnaire (NPI-Q);
Change From Baseline to Week 105 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score;
EQ-5D Questionnaire Domain Score for Participants;
Serum Concentration of Crenezumab;
Change From Baseline to Week 105 on Cognition, as Assessed by Alzheimer's Disease Assessment Scale-Cognition (ADAS-Cog) (Subscale) 11 (ADAS-Cog-11);
Change From Baseline to Week 105 on Function as Assessed by the ADCS-instrumental (ADCS-iADL) Subscore;
Percentage Change From Baseline to Week 105 in Hippocampal Volume as Determined by Magnetic Resonance Imaging (MRI);


________________________________________________________________
Riga 255 supera TOK_MAX (2387 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline in Regional Cerebral Blood Flow (rCBF) Using Florbetapir Perfusion Scan;
Change From Baseline in Whole Brain Volume;
Change From Baseline in CSF Biomarker Total Tau;
Change From Baseline in Functional Activities Questionnaire (FAQ) Score;
Change From Baseline in Brain Amyloid Burden Using Florbetapir Amyloid Positron Emission Tomography (PET) Scan;
Percent Change From Baseline in Concentration of CSF Biomarker Aβ1-40;
Change From Baseline in Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory Instrumental Items Score (ADCS-iADL);
Change From Baseline on the Mini-Mental State Examination (MMSE);
Population Pharmacokinetics (PK): Apparent Oral Clearance of Lanabecestat;
Change From Baseline in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score;
Time to Progression as Measured by Loss of Clinical Dementia Rating (CDR) Global Score Stage;
Population PK: Central Volume of Distribution of Lanabecestat;
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score;
Change From Baseline in Neuropsychiatric Inventory (NPI) Score;
Change From Baseline in CSF Biomarker Phosphorylated Tau;
Change From Baseline in Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog13) Score;
Percent Change From Baseline in Concentration of Cerebrospinal Fluid (CSF) Biomarker Amyloid Beta (Aβ)1-42;


________________________________________________________________
Riga 264 supera TOK_MAX (7311 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline Over Time in ADAS-Cog-14 Number Cancellation Score;
Change From Baseline Over Time in Neuropsychiatry Inventory (NPI) Total Score;
Change From Baseline Over Time in University of California's Performance Based Skills Assessment, Brief Version (UPSA-Brief) - Total Score;
Change From Baseline Over Time in ADCS-CGIC-MCI Behavior Score;
Change From Baseline Over Time in ADAS-Cog-14 Word Recognition Score;
Number of Participants With Treatment Emergent Adverse Events (TEAEs);
AUC0-28/Dose for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses;
Area Under the Concentration-Time Curve From Dosing (Time 0) to Day 28 (AUC0-28) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses;
Change From Baseline Over Time in ADCS-CGIC-MCI Functional Abilities Score;
Change From Baseline Over Time in CDR-SB Score;
Change From Baseline Over Time in Repeatable Battery for Assessment of Neuropsychological Status (RBANS) - Total Scale Score;
Change From Baseline Over Time in RBANS - Digit Span Total Score;
Change From Baseline Over Time in RBANS - Figure Recall Total Score;
Change From Baseline Over Time in ADAS-Cog-14 Commands Score;
Change From Baseline Over Time in RBANS - Coding Total Score;
Change From Baseline Over Time in Alzheimer's Disease Cooperative Study Clinical Global Impression of Change for Mild Cognitive Impairment (ADCS-CGIC-MCI) General Condition Score;
Change From Baseline Over Time in RBANS - Story Recall Total Score;
Change From Baseline Over Time in Functional Activities Questionnaire (FAQ) Score;
Change From Baseline Over Time in RBANS - Figure Copy Total Score;
Change From Baseline Over Time in RBANS - Story Memory Total Score;
Change From Baseline Over Time in ADAS-Cog-14 Orientation Score;
Change From Baseline Over Time in 24-Item Alzheimer's Disease Cooperative Study/Activities of Daily Living Scale Adapted for Patients With Mild Cognitive Impairment (ADCS-MCI-ADL-24) Total Score;
Change From Baseline Over Time in RBANS - List Recall Total Score;
Change From Baseline Over Time in RBANS - Semantic Fluency Total Score;
Change From Baseline Over Time in ADAS-Cog-14 Ideational Praxis Score;
Change From Baseline Over Time in ADAS-Cog-14 Word Recall - Number of Words Not Recalled Score;
Change From Baseline Over Time in ADAS-Cog-14 Delayed Word Recall Score;
Change From Baseline Over Time in RBANS - Picture Naming Total Score;
Change From Baseline Over Time in ADAS-Cog-14 Constructional Praxis Score;
Change From Baseline Over Time in Alzheimer's Disease Composite Score (ADCOMS) Score;
Change From Baseline Over Time in ADAS-Cog-14 Maze Task Score;
Change From Baseline Over Time in ADCS-CGIC-MCI Cognition Score;
Change From Baseline Over Time in ADAS-Cog-14 Remember Word Recognition Instructions Score;
Change From Baseline Over Time in ADAS-Cog-14 Spoken Language Ability Score;
Change From Baseline Over Time in ADAS-Cog-14 Comprehension of Spoken Language Score;
Change From Baseline Over Time in Mini-Mental State Examination (MMSE) Total Score;
Change From Baseline Over Time in ADAS-Cog-14 Word Find Difficulty Spontaneous Speech Score;
Change From Baseline Over Time in ADAS-Cog-14 Naming Score;
Change From Baseline Over Time in RBANS - Line Orientation Total Score;
Change From Baseline Over Time in Alzheimer's Disease Assessment Scale (14-Item) Cognition Portion (ADAS-Cog-14) Total Score;
Half-Life (T1/2) for ABBV-8E12 Over the Dosing Interval After the First and Fourth Doses;
Change From Baseline Over Time in RBANS - List Recognition Total Score;
Change From Baseline Over Time in RBANS - List Learning Total Score;


________________________________________________________________
Riga 267 supera TOK_MAX (3631 > 1700) – saltata.

outcome_measurement_title:
Core Phase: Change From Last Dose in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score;
Core Phase: Change From Last Dose in the ADAS-cog14 Score;
Core Phase: Change From Baseline up to Month 24 in the MMSE Score;
Core Phase: Change From Baseline up to Month 24 in Alzheimer's Disease Composite Score (ADCOMS);
Core Phase: Change Per Year (Mean Slope) in CDR-SB Score up to Month 24;
Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score;
Core Phase: Change From Last Dose in the CDR-SB Score;
Core Phase: Change From Baseline up to Month 24 in Amyloid Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVR);
Core Phase: Change From Baseline up to Month 24 in the Functional Assessment Questionnaire (FAQ) Score;
Core Phase: Change From Last Dose in the ADAS-cog11 Score;
Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs);
Core Phase: Time to Worsening of CDR Score up to Month 24;
Core Phase: Change From Baseline up to Month 24 in the CDR-SB Score for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6;
Core Phase: Change From Baseline up to Month 24 in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score;
Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition11 (ADAS-Cog11) Score;
Core Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 24;
Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition14 (ADAS-Cog14) Score;
Core Phase: Change From Baseline up to Month 24 in the ADCOMS for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6;
Core Phase: Change From Last Dose in the ADCOMS;
Core Phase: Change From Last Dose in the MMSE Score;


________________________________________________________________
Riga 277 supera TOK_MAX (3031 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline to Week 53 on Behavior in Neuropsychiatric Inventory Questionnaire (NPI-Q) Total Score;
Plasma Amyloid Beta (Abeta) 42 Concentrations;
Change From Baseline to Week 77 on Function as Assessed by the Functional Activities Questionnaire (FAQ) Total Score;
Change From Baseline to Week 77 in Alzheimer's Disease Assessment Scale-Cognition 13 (ADAS-Cog-13) Subscale Score;
Percentage Change From Baseline to Week 105 in Hippocampal Volume as Determined by Magnetic Resonance Imaging (MRI);
Percentage Change From Baseline to Week 105 in Whole Brain Volume as Determined by Magnetic Resonance Imaging (MRI);
Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) Scale Score;
Change From Baseline to Week 77 in Alzheimer's Disease Assessment Scale-Cognition 11 (ADAS-Cog-11) Subscale Score;
Change From Baseline to Week 77 on Function as Assessed by (ADCS-iADL) Instrumental Score;
European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Domain Scores for Caregivers;
Percentage of Participants With Adverse Event (AEs) and Serious Adverse Event (SAEs);
Percentage Change From Baseline to Week 105 in Ventricle Volume as Determined by Magnetic Resonance Imaging (MRI);
Change From Baseline to Week 77 on Severity of Dementia, Assessed Using the CDR-Global Score (CDR-GS);
Change From Baseline to Week 77 on Severity of Dementia, Assessed Using the Mini Mental State Evaluation (MMSE);
European Quality of Life-5 Dimensions (EQ-5D) Questionnaire Domain Scores for Participants;
Change From Baseline to Week 77 in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Scale Score;
Plasma Amyloid Beta (Abeta) 40 Concentrations;
Change From Baseline to Week 77 on Function as Assessed by (ADCS-ADL) Total Score;
Serum Concentration of Crenezumab;
Quality of Life-Alzheimer's Disease (QoL-AD) Scale Score;


________________________________________________________________
Riga 296 supera TOK_MAX (2804 > 1700) – saltata.

outcome_measurement_title:
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Phosphorylated Tau (pTau-181);
OLE Period : Number of Participants With Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by MRI;
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Total Tau (tTau);
DBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest;
DBT Period: Number of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab;
OLE Period: Number of Participants With Adverse Events (AEs);
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score;
DBT Period: Number of Participants With ARIA-E Confirmed by MRI;
DBT Period: Number of Participants With ARIA-H Confirmed by MRI;
DBT Period: Percent Change From Baseline to Week 116 in Cerebrospinal Fluid (CSF) Marker of Disease in a Subset of Participants - Neurofilament Light Chain (NFL);
DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB;
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score;
Change From Baseline to Week 116 in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a Subset of Participants;
DBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score;
DBT Period: Number of Participants With Injection-Site Reactions;
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score;
DBT Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS;
Change From Baseline to Week 116 in Brain Tau Load, as Measured by Tau PET Scan in a Subset of Participants;
DBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score;
OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS);
OLE Period: Number of Participants With Injection-Site Reactions;
DBT Period: Number of Participants With AEs;
OLE Period: Number of Participants With Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by Magnetic Resonance Imaging (MRI);
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score;
DBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score;


________________________________________________________________
Riga 297 supera TOK_MAX (2927 > 1700) – saltata.

outcome_measurement_title:
DBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score;
China - DBT Period: Number of Participants With at Least One ARIA-E MRI Finding;
DBT Period: Change From Baseline to Week 116 in Brain Tau Load, as Measured by Tau PET Scan in a Subset of Participants;
OLE Period: Number of Participants With at Least One ARIA-E MRI Finding;
DBT Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS);
China - DBT Period: Number of Participants With at Least One ARIA-H MRI Finding;
DBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest;
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Phosphorylated Tau (pTau-181);
DBT Period: Percent Change From Baseline to Week 116 in Cerebrospinal Fluid (CSF) Marker of Disease in a Subset of Participants - Total Tau (tTau);
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score;
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score;
DBT Period: Change From Baseline to Week 116 in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a Subset of Participants;
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score;
DBT Period: Number of Participants With Injection-Site Reactions;
DBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score;
China - DBT Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS;
OLE Period: Number of Participants With at Least One ARIA-H MRI Finding;
DBT Period: Number of Participants With at Least One Adverse Event (AE);
OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS;
OLE Period: Number of Participants With at Least One AEs;
China - DBT Period: Number of Participants With Injection-Site Reactions;
DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Magnetic Resonance Imaging (MRI) Finding;
DBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score;
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score;
DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) MRI Finding;
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurofilament Light Chain (NFL);
DBT Period: Number of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab;
DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB;
China - DBT Period: Number of Participants With at Least One AE;


________________________________________________________________
Riga 300 supera TOK_MAX (2453 > 1700) – saltata.

outcome_measurement_title:
Change From Baseline ADAS-Cog14 (Alzheimer's Disease Assessment Scale - Cognition Subscale);
Change From Baseline in the Cerebrospinal Fluid (CSF) Biomarkers;
Change From Baseline in the Imaging of [18F]FDG PET SUV Ratio (SUVR);
Change From Baseline in Volumetric Magnetic Resonance Imaging (MRI);
Change From Baseline in Mini Mental State Exam (MMSE);
Change From Baseline in the Imaging of Functional MRI - Intrinsic Connectivity Contrast (ICC);
Change From Baseline ADAS-Cog13 (Alzheimer's Disease Assessment Scale - Cognition Subscale);
Change From Baseline in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB);
Change From Baseline in Alzheimer's Disease Clinical Study - Clinician Global Impression of Change (ADCS-CGIC);
Change From Baseline in the Cognitive Composite;
Change From Baseline in ADCS-Activities of Daily Living (ADCS-ADL);
Change From Baseline in the Imaging of [11C] UCB-J PET Distribution Volume Ratio (DVR);
Change From Baseline in the Memory Composite;
Change From Baseline in the Executive Composite;
Number of TEAEs, Related TEAEs, SAEs, and Related SAEs;
Change From Baseline ADAS-Cog11 (Alzheimer's Disease Assessment Scale - Cognition Subscale);
Change From Baseline in Attention Composite;


________________________________________________________________
Riga 346 supera TOK_MAX (2779 > 1700) – saltata.

outcome_measurement_title:
Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) Confirmed by MRI;
Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Confirmed by MRI;
Change From Baseline Over Time in Clinical Dementia Rating - Global Score (CDR-GS);
Number of Participants With Anti-drug Antibody (ADA) to Gantenerumab;
Change From Baseline Over Time in Coding (Digit Symbol Substitution Test [DSST]) Subset;
Change From Baseline Over Time in Alzheimer Disease Assessment Scale-Cognition, Subscale 13 (ADAS-Cog13) Score;
Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS) Score;
Change From Baseline Over Time in Clinical Dementia Rating (CDR) - Sum of Boxes (SB);
Change From Baseline Over Time in Verbal Fluency Task Score;
Change From Baseline Over Time in Alzheimer Disease Assessment Scale-Cognition, Subscale 11 (ADAS-Cog11) Score;
Change in Alzheimer Disease Cooperative Study Group-Activities of Daily Living (ADCS-ADL) Score;
Change in Functional Activities Questionnaire (FAQ) Score;
Change From Baseline Over Time in Mini-Mental State Examination (MMSE) Score;
Number of Participants With Injection-Site Reactions (ISRs);
Number of Participants With at Least One Adverse Event of Special Interest (AESI);
Number of Participants Who Discontinued the Study Due an AE;
Number of Participants With at Least One Adverse Event (AE) and Serious Adverse Event (SAE);


________________________________________________________________
Riga 371 supera TOK_MAX (4276 > 1700) – saltata.

outcome_measurement_title:
Part 1: Change From Baseline in Respiratory Rate;
Part 1: Dose Normalized Area Under the Concentration Time Curve Over a Dosing Interval (AUCtau) of TB006;
Part 2: Change From Baseline in Temperature;
Part 2: Change From Baseline in ECG Mean Heart Rate;
Part 2: Change From Baseline in Respiratory Rate;
Part 1: Change From Baseline in Electrocardiogram (ECG) Mean Heart Rate;
Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein;
Part 2: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS;
Part 1: Number of Participants With Anti-TB006 Antibodies (Immunogenicity of TB006);
Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Volume (Ery. MCV);
Part 2: Change From Baseline in Urine Specific Gravity;
Part 1: Change From Baseline in Heart Rate;
Part 1: Volume of Distribution (Vd) of TB006;
Part 1: Change From Baseline in Hematology Parameter: Erythrocyte. Mean Corpuscular Hemoglobin (Ery. MCH);
Part 2: Change From Baseline in Urobilinogen;
Part 1: Change From Baseline in Hematology Parameter: Hemoglobin;
Part 1: Time at Which Maximum Plasma Concentration Occurs (Tmax) of TB006;
Part 2: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin;
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes;
Part 2: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium;
Part 2: Percentage of Responders on the Clinical Dementia Rating Scale - Sum of Boxes;
Part 1: Change From Baseline in Urine Potential of Hydrogen (pH);
Part 1: Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatine Kinase (CK);
Part 2: Change From Baseline in Hematology Parameter: Ery. MCV;
Part 2: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets;
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin and Protein;
Part 1: Change From Baseline in Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP);
Part 1: Change From Baseline in Urine Specific Gravity;
Part 1: Change From Baseline in Temperature;
Part 1: Change From Baseline in Urobilinogen;
Part 2: Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK;
Part 2: Ctrough of TB006;
Part 2: Change From Baseline Through Day 36 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score;
Part 2: Change From Baseline in ECG Parameters;
Part 2: Change From Baseline in Hematology Parameter: Hematocrit;
Part 1: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL (High Density Lipoprotein) Cholesterol, LDL (Low Density Lipoprotein) Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen;
Part 1: Dose Normalized Maximum Observed Plasma Concentration (Cmax) of TB006;
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes and Reticulocytes;
Part 2: Change From Baseline on Mini-Mental State Examination (MMSE) Score;
Part 2: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C;
Part 1: Concentration at the End of a Dosing Interval (Ctrough) of TB006;
Part 1: Change From Baseline in ECG Parameters;
Part 2: Change From Baseline in Chemistry Parameters: Calcium, Cholesterol, Creatinine, Direct Bilirubin, Glucose, HDL Cholesterol, LDL Cholesterol, Total Bilirubin, Triglycerides and Urea Nitrogen;
Part 2: Change From Baseline in Hematology Parameter: Hemoglobin;
Part 2: t1/2 of TB006;
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets;
Part 1: Terminal Elimination Phase Half-life (t1/2) of TB006;
Part 1: Total Clearance (CL) of TB006;
Part 2: Change From Baseline in Urine pH;
Part 2: Change From Baseline on the Neuropsychiatric Inventory (NPI) Score;
Part 1: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia Suicide Severity Rating Scale (C-SSRS);
Part 2: Number of Participants With AEs and SAEs;
Part 2: Change From Baseline in DBP and SBP;
Part 2: Change From Baseline Through Day 104 on the Clinical Dementia Rating Scale - Sum of Boxes Total Score;
Part 1: Change From Baseline in Clinical Chemistry Parameter: Hemoglobin A1C;
Part 2: Change From Baseline in Heart Rate;
Part 2: Change From Baseline in Hematology Parameter: Ery. MCH;
Part 1: Change From Baseline in Clinical Chemistry Parameters: Potassium and Sodium;
Part 1: Change From Baseline in Clinical Chemistry Parameter: Thyrotropin;
Part 1: Change From Baseline in Hematology Parameter: Hematocrit;
Part 2: Cmax of TB006;
